Creative Biolabs now provides bispecific antibody (BsAb) development services by utilizing hybrid–hybridoma technology, also known as quadroma approach, which is based on the somatic fusion of two different hybridoma cell lines that express their own monoclonal antibodies respectively, to produce BsAbs with the desired specificities.

Experts from Creative Biolabs use hybridoma cell lines from two different species (usually a mouse and a rat cell line) to establish our own production cell lines in order to reduce the Ig heavy chains and light chains mispairing. After the establishment of stable and high yield quadroma cell lines, a reliable, sensitive and fast screening assay of the hybrid hybridoma culture medium will be carried out as another round of quality certification for the BsAb targeting affinity. We can produce IgG-like bispecific antibodies either with research purpose or in large scale for commercial objective. Bispecific F(ab’)2 is also available upon request, which can be generated by removing Fc part of an IgG-like BsAb through enzymatic digestion. Taking advantage of the hybrid-hybridoma technology, Creative Biolabs is committed to offering customers top quality BsAb development services.

Flow chart of developing BsAbs via hybrid-hybridoma technology

We offer a full range of technological approaches needed for bispecific antibody development:

• Genetic Engineering
• Chemical Conjugation
• Hybrid–hybridoma Technology

Loading case studies...

For research use only. Not intended for any clinical use.